Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.
Foresight Diagnostics, which provides ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of the PRECISE-HL clinical trial with the University of Washington ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback